2019-01-10 17:31:00 Thu ET
stock market gold oil stock return s&p 500 asset market stabilization asset price fluctuations stocks bonds currencies commodities funds term spreads credit spreads fair value spreads asset investments
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would become an oncology powerhouse with $8 billion blockbuster medications. Celgene share price surges 21% as Bristol-Myers Squibb (BMS) announces this acquisition. When the deal closes, Celgene shareholders would receive one BMS share, $50 in cash for each Celgene share, and one tradeable contingent value right for each share of Celgene. This contingent value right entitles its holder to gain a one-time potential payment of $9 in cash upon FDA approval of all 3 main medications of ozanimod (31 December 2020), liso-cel (31 December 2020) and bb2121 (31 March 2021).
BMS already owns a rich portfolio of blockbuster medications. These medications include the top-selling PD-1 checkpoint inhibitor Opdivo, the leukemia drug Sprycel, the melanoma drug Yervoy, the multiple-myeloma drugs Revlimid and Pomalyst, and the pancreatic cancer medicine Abraxane. These medications generate about $5.9 billion revenue in 2018Q3. These landmark medications position BMS as the market-share leader in immune-oncology and hematology.
The BMS specialty market niche and patent portfolio collectively create competitive moats for the new biopharma goliath in comparison to Johnson & Johnson, Merck, Pfizer, Roche, and Novartis etc.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2023-12-03 11:33:00 Sunday ET

Macro innovations and asset alphas show significant mutual causation. April 2023 This brief article draws from the recent research publicati
2018-09-19 12:38:00 Wednesday ET

The Trump administration imposes 10% tariffs on $200 billion Chinese imports and expects to raise these tariffs to 25% additional duties toward the end of t
2017-12-23 10:40:00 Saturday ET

Despite having way more responsibility than anyone else, top business titans such as Warren Buffett, Charlie Munger, and Oprah Winfrey often step away from
2018-11-15 12:35:00 Thursday ET

Warren Buffett approves Berkshire Hathaway to implement new meaningful stock repurchases. Buffett sends a positive signal to the stock market with the Berks
2025-06-05 00:00:00 Thursday ET

Former New York Times team journalist and Pulitzer Prize winner Charles Duhigg describes, discusses, and delves into how we can change our respective lives
2018-08-07 07:33:00 Tuesday ET

President Trump sounds smart when he comes up with a fresh plan to retire $15 trillion national debt. This plan entails taxing American consumers and produc